Middle East Healthcare Co CJSC (4009) fair value: what the stock is really worth
We calculate from audited financials what Middle East Healthcare Co CJSC is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Middle East Healthcare Co CJSC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 24.44 SAR – 128.21 SAR · fair‑value band 40.98 SAR – 69.70 SAR · the 31.38 SAR price screens below the 55.76 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Middle East Healthcare Company, a healthcare provider, owns and operates a network of hospitals under the Saudi German Hospital name in the Kingdom of Saudi Arabia and internationally. The company operates, manages, and maintains hospitals; and medical, educational, rehabilitation, laboratories and radiology, physiotherapy, and pharmacies centers.
Show more
Middle East Healthcare Company, a healthcare provider, owns and operates a network of hospitals under the Saudi German Hospital name in the Kingdom of Saudi Arabia and internationally. The company operates, manages, and maintains hospitals; and medical, educational, rehabilitation, laboratories and radiology, physiotherapy, and pharmacies centers. It also buys land to construct medical projects, as well as to establish, manage, construct, and organize exhibitions. The company was founded in 1988 and is based in Jeddah, the Kingdom of Saudi Arabia. Middle East Healthcare Company operates as a subsidiary of Bait Al Batterjee Medical Co. Ltd.
Stock analysis
Middle East Healthcare Co CJSC (4009) currently trades at 31.38 SAR, while our model-based Fair Value estimate is 55.76 SAR, implying the stock looks roughly 43.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 58.54 SAR per share, and 10 of the 17 models we run sit above the 31.38 SAR price.
Bear case: the Dividend Discount group reads lowest at 7.56 SAR, and 7 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: 40.98 SAR (bear) to 69.70 SAR (bull), the price of 31.38 SAR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Middle East Healthcare Co CJSC reported revenue of 3.1B SAR in FY2025 versus 1.9B SAR in FY2021, a compound +13.5%/yr. Reported net income was 302M SAR in FY2025, compounding +125.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 2.9B SAR (≈ $769M) · P/E ratio 17.2 · P/S ratio 1.68 · EPS (TTM) 1.82 SAR · Dividend yield 1.6% · Net margin 9.7% · Return on equity 9.1% · Return on assets (EBIT) 5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at 78%, 4009 screens cheaper than that median.
Fair Value models
Bear 40.98 SARFair Value 55.76 SARBull 69.70 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.9294 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +32.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.5%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.30% vs −2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 13%
⚠ Rate on operating basis: 2025 sits 68% above its own trend.
Compare Middle East Healthcare Co CJSC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside+67% · Top 25%
Profitability
Return on equity (TTM)9% · Above median
Return on assets4% · Above median
Net margin (TTM)5% · Below median
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth4% · Below median
Dividend yield (TTM)1.6% · Below median
Balance sheet
Debt / equity0.85× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Middle East Healthcare Co CJSC Fair Value". https://www.fairvalue-calculator.com/stock/4009
Frequently asked questions
Is Middle East Healthcare Co CJSC (4009) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 55.76 SAR versus a price of 31.38 SAR, about +78% upside (undervalued).
What is the fair value of 4009?
Our model-based fair value for Middle East Healthcare Co CJSC is 55.76 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 31.38 SAR.
What is the quality score of 4009?
Middle East Healthcare Co CJSC has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Middle East Healthcare Co CJSC (4009)?
Our model-based price target is the fair value of 55.76 SAR (as of Sep 13, 2026) from 17 valuation models. Cautious scenario 40.98 SAR, optimistic scenario 69.70 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Middle East Healthcare Co CJSC stock forecast for 2026?
Our models put fair value at 55.76 SAR, about +78% upside versus a price of 31.38 SAR (undervalued). Cautious scenario 40.98 SAR, optimistic scenario 69.70 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Middle East Healthcare Co CJSC (4009)?
Middle East Healthcare Co CJSC reported trailing-twelve-month revenue of about 3.1B SAR (latest available figure, as of Sep 13, 2026).
Does Middle East Healthcare Co CJSC pay a dividend?
Middle East Healthcare Co CJSC currently shows a dividend yield of about 1.59% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Middle East Healthcare Co CJSC (4009)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Middle East Healthcare Co CJSC it is 55.76 SAR per share (as of Sep 13, 2026), against a price of 31.38 SAR. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Middle East Healthcare Co CJSC stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 4009 trades below its calculated fair value: price 31.38 SAR, fair value 55.76 SAR, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4009?
No. The price is what the market pays today (31.38 SAR); the fair value is what the company's own numbers justify (55.76 SAR). For Middle East Healthcare Co CJSC the two are 24.38 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Middle East Healthcare Co CJSC worth?
The market values Middle East Healthcare Co CJSC at about 2.9B SAR (market capitalisation, as of Sep 13, 2026). Per share that is 31.38 SAR; our models calculate a fair value of 55.76 SAR per share.
What do the bullish and bearish scenarios say about 4009?
Our models span a range for Middle East Healthcare Co CJSC: cautious scenario 40.98 SAR, base 55.76 SAR, optimistic 69.70 SAR per share (as of Sep 13, 2026, price 31.38 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4009?
Middle East Healthcare Co CJSC trades at a price-to-earnings ratio of 17.2 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 55.76 SAR is built from several models across several years. Other multiples: P/B 0.4, P/S 0.2, EV/EBITDA 4.0.
How solid is the balance sheet of Middle East Healthcare Co CJSC (4009)?
Balance-sheet figures for Middle East Healthcare Co CJSC (as of Sep 13, 2026): return on equity 9.1%, debt of 0.85 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 4009 from its 52-week high?
Middle East Healthcare Co CJSC trades at 31.38 SAR, about 47% below its 52-week high of 59.20 SAR and 11% above the low of 28.21 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 55.76 SAR is for.
Which stocks are comparable to Middle East Healthcare Co CJSC?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Middle East Healthcare Co CJSC stock attractive at the current price?
The data as of Sep 13, 2026: price 31.38 SAR, calculated fair value 55.76 SAR (+78%), Quality Score 42/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4009 calculated?
We run Middle East Healthcare Co CJSC through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 55.76 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Middle East Healthcare Co CJSC currently trades 78 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Middle East Healthcare Co CJSC right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (40.98 SAR). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Middle East Healthcare Co CJSC (4009) come from?
Earnings per share at Middle East Healthcare Co CJSC grew −3.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.4 %, EBIT margin −6.0 %, tax rate −0.8 %, residual (interest, one-offs) −3.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Middle East Healthcare Co CJSC
How large is the market capitalisation of Middle East Healthcare Co CJSC (4009)?
The market capitalisation of Middle East Healthcare Co CJSC is 2.9B SAR (≈ $769M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Middle East Healthcare Co CJSC (4009)?
The price-to-sales ratio of Middle East Healthcare Co CJSC is 1.68 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Middle East Healthcare Co CJSC (4009)?
Earnings per share at Middle East Healthcare Co CJSC are 1.82 SAR (price ÷ EPS = P/E 17.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Middle East Healthcare Co CJSC (4009)?
The dividend yield of Middle East Healthcare Co CJSC is 1.6% (payout 27.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Middle East Healthcare Co CJSC (4009)?
The net margin of Middle East Healthcare Co CJSC is 9.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Middle East Healthcare Co CJSC (4009)?
The return on equity (ROE) of Middle East Healthcare Co CJSC is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Middle East Healthcare Co CJSC (4009)?
On an EBIT basis the return on assets of Middle East Healthcare Co CJSC is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Middle East Healthcare Co CJSC (4009)?
The operating margin of Middle East Healthcare Co CJSC is 10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Middle East Healthcare Co CJSC (4009)?
Revenue at Middle East Healthcare Co CJSC is growing +4.3% versus a year earlier (3y avg +13.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Middle East Healthcare Co CJSC (4009)?
Earnings per share at Middle East Healthcare Co CJSC are growing −84.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Middle East Healthcare Co CJSC (4009) generate?
The free cash flow of Middle East Healthcare Co CJSC is −99.8M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Middle East Healthcare Co CJSC (4009) carry?
The net debt of Middle East Healthcare Co CJSC is 2.5B SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Middle East Healthcare Co CJSC in the live analysis
One click puts Middle East Healthcare Co CJSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
